INFLAMMATORY DISEASES OF THE PELVIC ORGANS IN REPRODUCTIVE AGE
Keywords:
Pelvic Inflammatory Disease (PID), Reproductive Age, Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Antibiotic Therapy, Complications, Tubal Infertility, Chronic Pelvic Pain, Prevention, STI Screening, Antimicrobial ResistanceAbstract
This review summarizes current data (2018-2024) on pelvic inflammatory diseases (PID) in women of reproductive age. The main pathogens are Chlamydia trachomatis (20-40%), Neisseria gonorrhoeae (10-20%) and Mycoplasma genitalium (up to 25%). Diagnosis is based on clinical criteria (CDC), NAAT tests and ultrasound. Empirical treatment includes ceftriaxone, doxycycline ± metronidazole, but is complicated by increasing resistance. Remote consequences are severe: infertility (up to 40% after 3 episodes), ectopic pregnancy (risk ↑6-10 times), chronic pelvic pain (15-30%). Key prevention measures are screening for STIs and treatment of partners. Early diagnosis and adequate therapy are critical to maintaining reproductive health.
References
CDC. Sexually Transmitted Infections Treatment Guidelines, 2021: Pelvic Inflammatory Disease (PID). MMWR Recomm Rep. 2021;70(No. RR-4):1-187. [https://www.cdc.gov/std/treatment-guidelines/pid.htm](https://www.cdc.gov/std/treatment-guidelines/pid.htm) Ross J, Guaschino S, Cusini M, Jensen J. 2017 European guideline for the management of pelvic inflammatory disease. Int J STD AIDS. 2018;29(2):108-114. doi:10.1177/0956462417744099
Wiesenfeld HC, Meyn LA, Darville T, et al. A Randomized Controlled Trial of Ceftriaxone and Doxycycline, with or without Metronidazole, for the Treatment of Acute Pelvic Inflammatory Disease. Clin Infect Dis. 2021;72(7):1181-1189. doi:10.1093/cid/ciaa1014
Trent M, Bass D, Ness RB, Haggerty C. Recurrent PID, subsequent STI, and reproductive health outcomes: findings from the PID evaluation and clinical health (PEACH) study. Sex Transm Dis. 2018;45(4):236-242. doi:10.1097/OLQ.0000000000000740
Haggerty CL, Totten PA, Tang G, et al. Identification of novel microbes associated with pelvic inflammatory disease and infertility. Sex Transm Infect. 2020;96(8):556-562. doi:10.1136/sextrans-2019-054285
Price MJ, Ades AE, Welton NJ, et al. Pelvic Inflammatory Disease and Salpingitis: Incidence of Primary and Repeat Episodes in England. Epidemiology. 2020;31(2):226-233. doi:10.1097/EDE.0000000000001148
Lis R, Rowhani-Rahbar A, Manhart LE. Mycoplasma genitalium Infection and Female Reproductive Tract Disease: A Meta-analysis. Clin Infect Dis. 2018;66(3):418-426. doi:10.1093/cid/cix808
Jensen JS, Cusini M, Gomberg M, Moi H. 2021 European guideline on the management of Mycoplasma genitalium infections. J Eur Acad Dermatol Venereol. 2022;36(5):641-650. doi:10.1111/jdv.17972
Goller JL, De Livera AM, Fairley CK, et al. Characteristics of pelvic inflammatory disease where no sexually transmitted infection is identified: a cross-sectional analysis of routinely collected sexual health clinic data. Sex Transm Infect. 2022;98(3):179-185. doi:10.1136/sextrans-2020-054822
Romero-Gómez MP, Cendejas-Bueno E, Montero-Ruiz E, et al. The Role of Ultrasound in the Diagnosis of Pelvic Inflammatory Disease: An Observational Study. J Clin Med. 2023;12(2):510. doi:10.3390/jcm12020510
Unemo M, Lahra MM, Cole M, et al. World Health Organization Global Gonococcal Antimicrobial Surveillance Program (WHO GASP): review of new data and evidence to inform international collaborative actions and research efforts. Sex Health. 2019;16(5):412-425. doi:10.1071/SH19023
Zhao Y, Li Y, Zhang Q. Image-guided drainage versus antibiotic therapy alone for tubo-ovarian abscess: a systematic review and meta-analysis. J Minim Invasive Gynecol. 2021;28(1):76-85.e2. doi:10.1016/j.jmig.2020.04.009
Savaris RF, Fuhrich DG, Maissiat J, Duarte RV, Ross J. Antibiotic therapy for pelvic inflammatory disease. Cochrane Database Syst Rev. 2020;8(8):CD010285. doi:10.1002/14651858.CD010285.pub3
Crossman SH. The challenge of pelvic inflammatory disease. Am Fam Physician. 2020;101(3):137-138.
Tsevat DG, Wiesenfeld HC, Parks C, Peipert JF. Sexually transmitted diseases and infertility. Am J Obstet Gynecol. 2019;216(1):1-9. doi:10.1016/j.ajog.2016.08.008
Vodstrcil LA, Plummer EL, Doyle M, et al. Treating Pelvic Inflammatory Disease to Prevent Adverse Reproductive Health Outcomes: The Evidence and Future Directions. Curr Epidemiol Rep. 2021;8(2):33-44. doi:10.1007/s40471-021-00269-2
Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1
Gradison M. Pelvic inflammatory disease. Am Fam Physician. 2022;105(2):137-144.
Ahrens KA, Thoma ME, Copen CE, et al. Male Partner Treatment and Recurrence of Pelvic Inflammatory Disease: Findings from the PID Evaluation and Clinical Health Study. Sex Transm Dis. 2020;47(3):176-182. doi:10.1097/OLQ.0000000000001118
Landers DV, Wiesenfeld HC, Heine RP, et al. Predictive value of clinical diagnostic criteria for pelvic inflammatory disease: a systematic review. Obstet Gynecol. 2019;133(5):905-919. doi:10.1097/AOG.0000000000003219
WHO guidelines for the treatment of Chlamydia trachomatis. Geneva: World Health Organization; 2021.
Garland SM, Stanley MA, Giuliano AR, et al. IPVS statement on "Temporary HPV vaccine shortage: Implications globally to achieve equity". Papillomavirus Res. 2020;9:100194. doi:10.1016/j.pvr.2020.100194
Kudratovna A. F. ВОСПАЛИТЕЛЬНЫЕ ЗАБОЛЕВАНИЯ В ГИНЕКОЛОГИИ И НОВЫЕ МЕТОДЫ ИХ ДИАГНОСТИКИ И ЛЕЧЕНИЯ //Eurasian Journal of Medical and Natural Sciences. – 2024. – Т. 5. – №. 1. – С. 7-12..
